LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

[1]  T. Hunter,et al.  An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy , 2021, Communications Biology.

[2]  Yi-Wen Chang,et al.  STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT–MET switch and cancer metastasis , 2020, Oncogene.

[3]  R. Jiang,et al.  The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer , 2020, Molecular Cancer.

[4]  E. Collisson,et al.  Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer , 2019, Nature Communications.

[5]  Kam Y. J. Zhang,et al.  EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer , 2019, Molecular Cancer Therapeutics.

[6]  Galina A. Erikson,et al.  Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring , 2019, Nature.

[7]  L. Orlando,et al.  Targeting triple negative breast cancer with histone deacetylase inhibitors , 2017, Expert opinion on investigational drugs.

[8]  N. Nikiteas,et al.  Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises. , 2017, Cancer genomics & proteomics.

[9]  G. Raj,et al.  Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers , 2017, eLife.

[10]  Katherine C. Sexton,et al.  Genomic regulation of invasion by STAT3 in triple negative breast cancer , 2016, Oncotarget.

[11]  Min Huang,et al.  Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer. , 2016, Cancer cell.

[12]  Joshua R. Johnson,et al.  Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow , 2016, Nature Cell Biology.

[13]  M. Arock,et al.  The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment , 2015, International journal of cancer.

[14]  B. Liu,et al.  Leukemia inhibitory factor promotes tumor growth and metastasis in human osteosarcoma via activating STAT3 , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[15]  A. Floreani,et al.  Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation , 2015, Oncotarget.

[16]  Wenwei Hu,et al.  LIF is a new p53 negative regulator. , 2015, Journal of nature and science.

[17]  Rory Stark,et al.  Progesterone receptor modulates estrogen receptor-α action in breast cancer , 2015, Nature.

[18]  Wenwei Hu,et al.  HIF-2α mediates hypoxia-induced LIF expression in human colorectal cancer cells , 2015, Oncotarget.

[19]  C. Caldas,et al.  Progesterone receptor modulates ERa action in breast cancer , 2015 .

[20]  K. Young,et al.  LIF negatively regulates tumor suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers , 2014, Nature Communications.

[21]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[22]  M. Ferrari,et al.  XBP1 Promotes Triple Negative Breast Cancer By Controlling the HIF1 α Pathway , 2014, Nature.

[23]  Zhen Liu,et al.  LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway , 2014, Oncotarget.

[24]  R. Johnstone,et al.  New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.

[25]  Ying Liang,et al.  Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. , 2013, The Journal of clinical investigation.

[26]  A. Bosserhoff,et al.  Impact of LIF (leukemia inhibitory factor) expression in malignant melanoma. , 2013, Experimental and molecular pathology.

[27]  R. Vadlamudi,et al.  PELP1 oncogenic functions involve CARM1 regulation. , 2013, Carcinogenesis.

[28]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[29]  Peijing Zhang,et al.  LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker , 2012, Nature Medicine.

[30]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[31]  A. Brenner,et al.  Therapeutic Significance of Estrogen Receptor β Agonists in Gliomas , 2012, Molecular Cancer Therapeutics.

[32]  J. Shin,et al.  Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer , 2011, Molecules and cells.

[33]  L. Carey,et al.  Triple-negative breast cancer: disease entity or title of convenience? , 2010, Nature Reviews Clinical Oncology.

[34]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[35]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[36]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[37]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[38]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[39]  D. Allred,et al.  Development of Standard Estrogen and Progesterone Receptor Immunohistochemical Assays for Selection of Patients for Antihormonal Therapy , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[40]  P. Marks,et al.  Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.

[41]  M. Ogawa,et al.  Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression. , 2007, International journal of oncology.

[42]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Dalton,et al.  LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism , 2005, Development.

[44]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[45]  S. Melmed,et al.  Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. , 2000, Endocrine reviews.

[46]  Z. Estrov,et al.  Leukemia‐inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways , 1996, International journal of cancer.

[47]  G. Yancopoulos,et al.  Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. , 1994, Science.

[48]  D. Metcalf.  The leukemia inhibitory factor (LIF). , 1991, International journal of cell cloning.